Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
roche
6
×
san francisco blog main
san francisco top stories
biotech
boston blog main
boston top stories
cancer
clinical trials
amgen
national
raleigh-durham blog main
raleigh-durham top stories
avapritinib
blueprint medicines
boston
bristol-myers squibb
cancer drugs
deals
eli lilly
fda
genentech
glaxosmithkline
indiana blog main
indiana top stories
investing
medullary thyroid cancer
merck
new york blog main
new york top stories
non-small cell lung cancer
novartis
pfizer
pralsetinib
san diego blog main
san diego top stories
seattle blog main
seattle top stories
What
cancer
6
×
drug
medicines
approval
blueprint
fda
ipo
medical
ret
address
advanced
annual
approves
arrival
ash
award
barcelona
bio
blood
broader
candidate
carries
certain
clinical
company
conference
currently
data
death
decades
december's
dems
designed
despite
detect
developing
esmo
european
family
files
Language
unset
6
×
Current search:
roche
×
unset
×
cancer
×
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More